Differential Treatment Outcomes in BRCA1/2 ‐, CDK12 ‐, and ATM ‐Mutated Metastatic Castration‐Resistant Prostate Cancer

Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: analysis from the phase 2 TRITON2 study

(2020) Wassim Abida et al.   CLINICAL CANCER RESEARCH

Pan-cancer Analysis of CDK12 Alterations Identifies a Subset of Prostate Cancers with Distinct Genomic and Clinical Characteristics

(2020) Bastien Nguyen et al.   EUROPEAN UROLOGY

Olaparib for Metastatic Castration-Resistant Prostate Cancer

(2020) Johann de Bono et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prognostic Value of Germline DNA Repair Gene Mutations in De Novo Metastatic and Castration‐Sensitive Prostate Cancer

(2020) Yu Wei et al.   ONCOLOGIST

Targeting CDK12 for cancer therapy: function, mechanism, and drug discovery

(2020) Hui Liu et al.   CANCER RESEARCH

PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer

(2019) Elena Castro et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): Preliminary results of GALAHAD.

(2019) Matthew Raymond Smith et al.   JOURNAL OF CLINICAL ONCOLOGY

Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations

(2019) Catherine H. Marshall et al.   EUROPEAN UROLOGY

846PDPreliminary results from the TRITON2 study of rucaparib in patients (pts) with DNA damage repair (DDR)-deficient metastatic castration-resistant prostate cancer (mCRPC): Updated analyses

(2019) W Abida et al.   ANNALS OF ONCOLOGY

LBA12_PRPROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations

(2019) M Hussain et al.   ANNALS OF ONCOLOGY

Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer

(2019) Melissa A. Reimers et al.   EUROPEAN UROLOGY

Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study

(2019) Emmanuel S. Antonarakis et al.   JOURNAL OF CLINICAL ONCOLOGY

The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact

(2019) Lisanne F. van Dessel et al.   Nature Communications

Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial

(2019) Daniel J Khalaf et al.   LANCET ONCOLOGY

Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial

(2019) Joaquin Mateo et al.   LANCET ONCOLOGY

The Tandem Duplicator Phenotype Is a Prevalent Genome-Wide Cancer Configuration Driven by Distinct Gene Mutations

(2018) Francesca Menghi et al.   CANCER CELL

Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer

(2018) Yi-Mi Wu et al.   CELL

Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer

(2018) David A. Quigley et al.   CELL

Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide

(2018) Emmanuel S. Antonarakis et al.   EUROPEAN UROLOGY

Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study

(2018) Joaquin Mateo et al.   EUROPEAN UROLOGY

Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012

(2018) Maha Hussain et al.   JOURNAL OF CLINICAL ONCOLOGY

Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer

(2018) Matti Annala et al.   Cancer Discovery

Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair–deficient Prostate Cancer

(2017) Matti Annala et al.   EUROPEAN UROLOGY

Biallelic Inactivation of BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer

(2016) Heather H. Cheng et al.   EUROPEAN UROLOGY

Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer

(2016) Colin C. Pritchard et al.   NEW ENGLAND JOURNAL OF MEDICINE

The tandem duplicator phenotype as a distinct genomic configuration in cancer

(2016) Francesca Menghi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Integrative Clinical Genomics of Advanced Prostate Cancer

(2015) Dan Robinson et al.   CELL

Targeting the DNA Damage Response in Cancer

(2015) Mark J. O’Connor   MOLECULAR CELL

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

(2015) Joaquin Mateo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone

(2014) Daniel L. Suzman et al.   PROSTATE